EA2176: Phase 3 Clinical Trial of Carboplatin and Pacliitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This phase 3 trial compares the addition of nivolumab to chemotherapy (carboplatin and
paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that
has spread to other places in the body (metastatic). Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as
carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving nivolumab together with carboplatin and paclitaxel may help doctors find out if the
treatment is better or the same as the usual approach.